GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcturus Therapeutics Holdings Inc (NAS:ARCT) » Definitions » 3-Year EPS without NRI Growth Rate

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) 3-Year EPS without NRI Growth Rate : 15.80% (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Arcturus Therapeutics Holdings 3-Year EPS without NRI Growth Rate?

Arcturus Therapeutics Holdings's EPS without NRI for the three months ended in Mar. 2024 was $-1.00.

During the past 12 months, Arcturus Therapeutics Holdings's average EPS without NRI Growth Rate was -233.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was 15.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Arcturus Therapeutics Holdings was 52.70% per year. The lowest was -89.40% per year. And the median was -0.20% per year.


Competitive Comparison of Arcturus Therapeutics Holdings's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Arcturus Therapeutics Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcturus Therapeutics Holdings's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Arcturus Therapeutics Holdings's 3-Year EPS without NRI Growth Rate falls into.



Arcturus Therapeutics Holdings 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Arcturus Therapeutics Holdings  (NAS:ARCT) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Arcturus Therapeutics Holdings 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Arcturus Therapeutics Holdings's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
10628 Science Center Drive, Suite 250, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.
Executives
Pad Chivukula officer: Chief Scientific Officer & COO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Keith C Kummerfeld officer: See Remarks 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
Joseph E Payne director, 10 percent owner, officer: President and CEO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Jing L. Marantz director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Ultragenyx Pharmaceutical Inc. director, 10 percent owner 60 LEVERONI COURT, NOVATO CA 94949
Lance Kurata officer: Chief Legal Officer 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Andy Sassine officer: Chief Financial Officer 82 DEVONSHIRE STREET, BOSTON MA 02109
Steven George Hughes officer: Chief Development Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
James F Barlow director 2525 DUPONT DR, IRVINE CA 92612
Edward W Holmes director C/O TULARIK INC, TWO CORP DRIVE SOUTH, SAN FRANCISCO CA 8608257208
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Karah Herdman Parschauer director 60 LEVERONI COURT, NOVATO CA 94949

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Headlines

From GuruFocus

Arcturus Appoints John Markels, Ph.D. to its Board of Directors

By Business Wire Business Wire 12-13-2022

Arcturus Therapeutics to Attend the Following Investor Conferences

By Business Wire Business Wire 09-01-2022